The effect of low-dose cyclophosphamide and immunologic exposure upon growth of established Dunning R-3327-G subline rat prostate adenocarcinomas.
Utilizing the Dunning rat prostate adenocarcinoma, a low dose of cyclophosphamide (CY), 30 mg/kg, administered either alone or following diethylstilbestrol (DES) therapy, was as effective as higher levels of CY (100 mg/kg) in ability to initiate tumor regression. A lower dose (10 mg/kg) of CY was initially ineffective. Animals which had been injected with tumor an additional 10 days prior to initiation of CY treatment were apparently more responsive to this mode of chemotherapy. The effect of this additional 10 days of immunologic exposure supports the belief that the activity of CY is augmented by the presence of immunologic competence. All animals which responded favorably toward therapy utilizing CY, alone or in combination with DES, were similarly able to reject subsequent tumor challenges. It is thought that low-dose CY may reduce the immunosuppressive effects observed with higher levels and presumably preserve the helper T cell population necessary to mount secondary immune responses.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000276:immunology; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002460:Cell Line; D002478:Cells, Cultured; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004054:Diethylstilbestrol / Q000008:administration & dosage; D004353:Drug Evaluation, Preclinical; D007121:Immunocompetence / Q000187:drug effects; D008297:Male; D009368:Neoplasm Transplantation; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000276:immunology; D051381:Rats; D011916:Rats, Inbred F344; D013997:Time Factors
D004054:Diethylstilbestrol; D003520:Cyclophosphamide